JP2015107945A - 神経新生に関する化合物及び医薬組成物 - Google Patents

神経新生に関する化合物及び医薬組成物 Download PDF

Info

Publication number
JP2015107945A
JP2015107945A JP2013252443A JP2013252443A JP2015107945A JP 2015107945 A JP2015107945 A JP 2015107945A JP 2013252443 A JP2013252443 A JP 2013252443A JP 2013252443 A JP2013252443 A JP 2013252443A JP 2015107945 A JP2015107945 A JP 2015107945A
Authority
JP
Japan
Prior art keywords
group
compound
prodrug
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013252443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015107945A5 (enExample
Inventor
正敏 萩原
Masatoshi Hagiwara
正敏 萩原
亜希子 小林
Akiko Kobayashi
亜希子 小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University
Original Assignee
Kyoto University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University filed Critical Kyoto University
Priority to JP2013252443A priority Critical patent/JP2015107945A/ja
Priority to PCT/JP2014/082035 priority patent/WO2015083750A1/ja
Priority to US15/101,862 priority patent/US20160303089A1/en
Publication of JP2015107945A publication Critical patent/JP2015107945A/ja
Publication of JP2015107945A5 publication Critical patent/JP2015107945A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Developmental Biology & Embryology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013252443A 2013-12-05 2013-12-05 神経新生に関する化合物及び医薬組成物 Pending JP2015107945A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2013252443A JP2015107945A (ja) 2013-12-05 2013-12-05 神経新生に関する化合物及び医薬組成物
PCT/JP2014/082035 WO2015083750A1 (ja) 2013-12-05 2014-12-03 神経新生に関する化合物及び医薬組成物
US15/101,862 US20160303089A1 (en) 2013-12-05 2014-12-03 Compound pertaining to neuropoiesis and drug composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013252443A JP2015107945A (ja) 2013-12-05 2013-12-05 神経新生に関する化合物及び医薬組成物

Publications (2)

Publication Number Publication Date
JP2015107945A true JP2015107945A (ja) 2015-06-11
JP2015107945A5 JP2015107945A5 (enExample) 2017-01-19

Family

ID=53273511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013252443A Pending JP2015107945A (ja) 2013-12-05 2013-12-05 神経新生に関する化合物及び医薬組成物

Country Status (3)

Country Link
US (1) US20160303089A1 (enExample)
JP (1) JP2015107945A (enExample)
WO (1) WO2015083750A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531143A (ja) * 2013-09-12 2016-10-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ インドール−カルボキサミド誘導体
WO2021153665A1 (ja) * 2020-01-30 2021-08-05 カルナバイオサイエンス株式会社 新規アルキン誘導体
JPWO2022059779A1 (enExample) * 2020-09-18 2022-03-24
JPWO2022186089A1 (enExample) * 2021-03-03 2022-09-09
WO2023008472A1 (ja) * 2021-07-28 2023-02-02 カルナバイオサイエンス株式会社 新規ベンゾチアゾール誘導体

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018043674A1 (ja) * 2016-08-31 2018-03-08 国立大学法人京都大学 神経新生を活性化するための組成物
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
CN110312528B (zh) 2017-02-20 2022-02-18 国立大学法人京都大学 用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法
US12605368B2 (en) 2020-04-01 2026-04-21 Kyoto University Suppression of neuroinflammation and composition and method therefor
EP4353260A4 (en) 2021-06-01 2025-06-04 Kyoto University METHOD FOR ENHANCING THE INNATE IMMUNE RESPONSE
JPWO2023008470A1 (enExample) * 2021-07-28 2023-02-02

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010797A1 (ja) * 2008-07-23 2010-01-28 株式会社キノファーマ Ｄｙｒｋを阻害する化合物を含有する医薬組成物
WO2011068990A1 (en) * 2009-12-04 2011-06-09 Medipropharma, Inc. Compositions and methods for inhibiting dyrk1a to treat central nervous system diseases and disorders
WO2011133795A2 (en) * 2010-04-22 2011-10-27 The Brigham And Women's Hospital, Inc. Beta-carbolines as inhibitors of haspin and dyrk kinases
JP2013505299A (ja) * 2009-09-22 2013-02-14 ニューロナセント インコーポレイテッド ダウン症を治療するための方法および薬学的組成物
WO2013026806A1 (en) * 2011-08-19 2013-02-28 Exonhit Sa Dyrk1 inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003273351A1 (en) * 2002-09-24 2004-04-19 Isis Pharmaceutical, Inc. Methods for blocking adipocyte differentiation and triglyceride accumulation with dual-specificity tyrosine- (y) - phosphorylation regulated kinase 4 (dyrk4) inhibitors
US20100184774A1 (en) * 2007-06-01 2010-07-22 Duffy Kevin J Methods of treatment
US20150133467A1 (en) * 2012-06-06 2015-05-14 Kyoto University Screening method, protein instability and/or stability inducers, and protein activity assessment
WO2014021337A1 (ja) * 2012-07-30 2014-02-06 国立大学法人京都大学 精神神経疾患又は悪性腫瘍に関する化合物及び医薬組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010797A1 (ja) * 2008-07-23 2010-01-28 株式会社キノファーマ Ｄｙｒｋを阻害する化合物を含有する医薬組成物
JP2013505299A (ja) * 2009-09-22 2013-02-14 ニューロナセント インコーポレイテッド ダウン症を治療するための方法および薬学的組成物
WO2011068990A1 (en) * 2009-12-04 2011-06-09 Medipropharma, Inc. Compositions and methods for inhibiting dyrk1a to treat central nervous system diseases and disorders
WO2011133795A2 (en) * 2010-04-22 2011-10-27 The Brigham And Women's Hospital, Inc. Beta-carbolines as inhibitors of haspin and dyrk kinases
WO2013026806A1 (en) * 2011-08-19 2013-02-28 Exonhit Sa Dyrk1 inhibitors and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF NEUROSCIENCE RESEARCH, vol. 90, JPN6017031570, 2012, pages 999 - 1010, ISSN: 0003753051 *
PHYTOTHERAPY RESEARCH, vol. 27, no. 7, JPN6017031568, 2010, pages 1065 - 1070, ISSN: 0003753049 *
THE FEBS JOURNAL, vol. 278, JPN6017031569, 2011, pages 246 - 256, ISSN: 0003753050 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531143A (ja) * 2013-09-12 2016-10-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ インドール−カルボキサミド誘導体
WO2021153665A1 (ja) * 2020-01-30 2021-08-05 カルナバイオサイエンス株式会社 新規アルキン誘導体
JPWO2021153665A1 (enExample) * 2020-01-30 2021-08-05
JPWO2022059779A1 (enExample) * 2020-09-18 2022-03-24
JP7706775B2 (ja) 2020-09-18 2025-07-14 カルナバイオサイエンス株式会社 アミン誘導体
JP2025134941A (ja) * 2020-09-18 2025-09-17 カルナバイオサイエンス株式会社 アミン誘導体
JPWO2022186089A1 (enExample) * 2021-03-03 2022-09-09
JP7800929B2 (ja) 2021-03-03 2026-01-16 国立研究開発法人理化学研究所 神経変性疾患治療のためのポリヌクレオチド、ベクター、細胞、医薬組成物及びスクリーニング方法
WO2023008472A1 (ja) * 2021-07-28 2023-02-02 カルナバイオサイエンス株式会社 新規ベンゾチアゾール誘導体

Also Published As

Publication number Publication date
US20160303089A1 (en) 2016-10-20
WO2015083750A1 (ja) 2015-06-11

Similar Documents

Publication Publication Date Title
WO2015083750A1 (ja) 神経新生に関する化合物及び医薬組成物
TWI721016B (zh) B型肝炎核心蛋白質調節劑
US10017524B2 (en) Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor
JP5820921B2 (ja) １，２−二置換複素環式化合物
EP3424912B1 (en) 2-aminothiazole derivatives, preparation and use thereof
JP5747142B2 (ja) Ｄｙｒｋを阻害する化合物を含有する医薬組成物
US6353010B1 (en) Bicyclic aryl carboxamides and their therapeutic use
CN116574105B (zh) 具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物
CN103889953A (zh) 作为防乙肝病毒感染的抗病毒剂的氨磺酰苯甲酰胺衍生物
JP2018514524A (ja) ５−芳香族アルキニル基置換ベンズアミド系化合物並びにその製造方法、薬物組成物及び使用
JP7110338B2 (ja) ムスカリンｍ１受容体陽性アロステリックモジュレーターである多環式アミド類
CN103189357B (zh) 作为kcnq2/3调节剂的取代的2-氧代-和2-硫代-二氢喹啉-3-甲酰胺
JP7104783B2 (ja) ムスカリンｍ１受容体陽性アロステリックモジュレーターであるヘテロアリール化合物
US20200078319A1 (en) Pharmaceutical composition, containing nm23 activator, for inhibiting cancer metastasis
JP7054524B2 (ja) 神経新生を活性化するための組成物
TW202214574A (zh) 經取代之(呔-1-基甲基)脲類、經取代之n-(呔-1-基甲基)醯胺類及其類似物
CN105829291B (zh) 与疼痛有关的化合物及医药组合物
KR101709731B1 (ko) 벤조옥사졸 또는 벤조티아졸 화합물, 그의 제조, 및 용도
JP2018016572A (ja) Ｎ−ピリダジン−３−イルスルホンアミド誘導体
JPWO2009153897A1 (ja) ステモナミド合成中間体ならびにがんを予防および／または治療するための医薬組成物
KR20200078921A (ko) N-아실유레아 유도체를 함유하는 평활근세포 증식, 부착 또는 이동 억제용 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170824

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180306